Iovance Biotherapeutics announces updated clinical data for Lifileucel

Iovance Biotherapeutics announced the publication of abstracts reporting clinical data and a trial in progress, TIP, for Iovance tumor-infiltrating lymphocyte, TIL, cell therapies for the upcoming Society for Immunotherapy of Cancer, SITC, Annual Meeting, November 8-12, 2022, in Boston, MA and virtually. The abstract reports on pooled consecutive cohorts from the C-144-01 trial with efficacy data from a total of 153 patients with advanced melanoma enrolled in Cohort 2 and Cohort 4. All patients had progressed on or after immune checkpoint inhibitor therapy, and targeted BRAF/MEK therapy where appropriate. Patients were heavily pre-treated and had substantial disease burden at baseline. The ORR assessed by an independent review committee using RECIST v1.1 was 31%, with 8 complete responses and 40 partial responses. mDOR was not reached, 42% of responses extended beyond 18 months, and 40% of responses were ongoing at the median study follow-up of 27.6 months. Median overall survival was 13.9 months. In patients who achieved a response at their first assessment, mOS had not been reached. The treatment-emergent adverse event profile was consistent with the underlying disease and known adverse event profiles of nonmyeloablative lymphodepletion and interleukin-2.